1
|
Chen L, Huang D, Mou X, Chen Y, Gong Y, He J. Investigation of quality of life and relevant influence factors in patients awaiting lung transplantation. J Thorac Dis 2012; 3:244-8. [PMID: 22263098 DOI: 10.3978/j.issn.2072-1439.2010.08.03] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2011] [Accepted: 08/24/2011] [Indexed: 11/14/2022]
Abstract
PURPOSE To investigate the quality of life and influence factors in patients awaiting lung transplantation. METHODS Fifty five participants who waited for lung transplantation were enrolled and received multiple surveys including Short Form 36 Health Survey Questionnaires (SF-36), Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS) and Perceiving Social Support Scale (PSSS). RESULTS The subjects awaiting lung transplant scored ranging from (23.18±37.53) to (74.57±26.02) regarding SF-36, significantly lower than norms (p<0.01); they scored (48.09±9.06) and ( 52.18±9.98) in SAS and SDS respectively, which were significant higher compared with norms (p<0.01), the patients scored (5.56±1.04) regarding social total support factor in PSSS questionnaire, and the scores of family support factor was significantly higher than that of outside family support factor (p<0.05). Single factor analysis revealed that the factors affecting quality of life included monthly family per capita income, medical cost source, dyspnea, BMI, anxiety, depression, and social support (p<0.05). Multiple factor analysis screened dyspnea (p<0.001) and depression (p<0.05) as influence factors of quality of life in patients awaiting lung transplantation. CONCLUSION Affected by various factors, the quality of life in patients awaiting lung transplant surgery is relatively poor, among which dyspnea and depression are dominant influence factors. Therefore, clinicians should take psychological and physiological measures to effectively enhance the quality of life in patients awaiting lung transplantation.
Collapse
Affiliation(s)
- Lihua Chen
- Department of Cardiothoracic Surgery, The First Hospital Affiliated to Guangzhou Medical College, Guangzhou Institute of Respiratory Disease, State Key Laboratary of Respiratory Disease
| | | | | | | | | | | |
Collapse
|
2
|
|
3
|
Abstract
Significant advances in the treatment of pulmonary arterial hypertension have occurred in the last several years. The decision to refer a patient for transplantation requires a dynamic approach. Candidate selection and timing of referral to transplant centers is critical for success, particularly with current allocation protocols that do not take into account the severity of illness. Though long-term success is tempered by chronic allograft dysfunction and infection, considerable improvements in outcomes have established lung transplantation for pulmonary arterial hypertension as an efficacious and life-prolonging treatment. However, transplantation should be reserved for patients who have failed the best available medical therapy. Ideally, transplantation occurs when the clinically deteriorating patient has enough reserve to survive long enough to be transplanted but is not debilitated enough to jeopardize the graft. There is significant uncertainty with regard to this ideal.
Collapse
Affiliation(s)
- Edward Cantu
- Department of Surgery, Duke University Medical Center, Durham, North Carolina
| | - R. Duane Davis
- Department of Surgery, Duke University Medical Center, Durham, North Carolina
| |
Collapse
|
4
|
Bazán Milián M, Delgado Bereijo L, González Jiménez N. Morbimortality in Heart and Lung Transplantation in Cuba: A 20-Year Follow-up. Transplant Proc 2009; 41:3507-9. [DOI: 10.1016/j.transproceed.2009.09.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
5
|
Interventional Lung Assist: A New Concept of Protective Ventilation in Bridge to Lung Transplantation. ASAIO J 2008; 54:3-10. [DOI: 10.1097/mat.0b013e318161d6ec] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
|
6
|
Takaoka S, Faul JL, Doyle R. Current therapies for pulmonary arterial hypertension. Semin Cardiothorac Vasc Anesth 2007; 11:137-48. [PMID: 17536117 DOI: 10.1177/1089253207301356] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature, characterized by relentless deterioration and death. Patients with PAH are known to be at increased risk for anesthetic complications and surgical morbidity and mortality. However, outcomes in patients have improved with the recent development of new drug therapies. The 3 major drug classes for treatment of PAH are prostanoids, endothelin-receptor antagonists, and phosphodiesterase-5 inhibitors. In this review, the authors provide an overview of each drug class, its mechanism of action, indications, and current supportive literature. Surgical and interventional treatments of PAH, including atrial septostomy, pulmonary thromboendarterectomy, and transplantation, are briefly reviewed, and the rationale, indications, and selection criteria for each are discussed. Although available medical and surgical therapies for PAH have improved patient outcomes, acute decompensated right heart failure (RHF) remains a common and challenging complication of PAH. The authors review this topic and provide an outline of the general pathophysiology of RHF and an approach to its management.
Collapse
Affiliation(s)
- Shanon Takaoka
- Division of Pulmonary/Critical Care Medicine, Stanford University Medical Center, Stanford, California 94305, USA
| | | | | |
Collapse
|
7
|
Biadi O, Potena L, Fearon WF, Luikart HI, Yeung A, Ferrara R, Hunt SA, Mocarski ES, Valantine HA. Interplay Between Systemic Inflammation and Markers of Insulin Resistance in Cardiovascular Prognosis After Heart Transplantation. J Heart Lung Transplant 2007; 26:324-30. [PMID: 17403472 DOI: 10.1016/j.healun.2007.01.020] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2006] [Revised: 12/05/2006] [Accepted: 01/08/2007] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Metabolic and immuno-inflammatory risk factors contribute to cardiac allograft vasculopathy (CAV) pathogenesis. Although systemic inflammation, as detected by C-reactive protein (CRP), predicts CAV development, the relationship between CRP and markers of metabolic abnormalities remains unexplored. METHODS CRP and the entire metabolic panel were evaluated in 98 consecutive heart transplant recipients at the time of annual coronary angiography, 5.8 years after transplant (range, 1-12 years). A ratio of triglycerides (TG) to high-density lipoproteins (HDL) of 3.0 or more was considered a marker of insulin resistance. CAV prevalence was defined by angiography, and subsequent prognosis was evaluated as incidence of major cardiac adverse events. RESULTS CRP was higher in the 34 patients with angiographic CAV than in those without CAV (1.10 +/- 0.20 vs 0.50 +/- 0.05 mg/dl, p < 0.001). Patients with insulin resistance had higher CRP concentrations (p = 0.023) and higher CAV prevalence (p = 0.005). High CRP and a TG/HDL of 3.0 or more were independently associated with an increased likelihood of CAV (odds ratio, > or = 3.9; p = 0.02) and predicted an increased risk of major cardiac adverse events. The combination of high CRP and a TG/HDL of 3.0 or more identified a subgroup of patients having a 4-fold increased risk for CAV and a 3-fold increased risk for major cardiac adverse events compared with patients with low CRP and normal values for metabolic indicators. CONCLUSIONS Both CRP and insulin resistance, as estimated by TG/HDL, appear to be strong, synergic risk factors for CAV and for major cardiac adverse events. These findings support the hypothesis that in heart transplant recipients, systemic inflammation may be an important mediator of graft vascular injury associated with metabolic syndrome.
Collapse
Affiliation(s)
- Ombretta Biadi
- Division of Cardiovascular Medicine, Stanford University, Stanford, California, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Miller CB, Malaisrie SC, Patel J, Garrity E, Vigneswaran WT, Gamelli RL. Intraabdominal complications after lung transplantation. J Am Coll Surg 2006; 203:653-60. [PMID: 17084326 DOI: 10.1016/j.jamcollsurg.2006.07.024] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2005] [Revised: 06/14/2006] [Accepted: 07/24/2006] [Indexed: 12/21/2022]
Abstract
BACKGROUND Because more lung transplant recipients survive the perioperative period, nonpulmonary complications become a major source of morbidity and mortality. Of these, intraabdominal complications are of particular concern because of the potential need for surgical intervention. So appropriate management of these complications becomes paramount. STUDY DESIGN We retrospectively reviewed 229 lung transplant recipients in a university medical center, between January 1997 and December 2004 developed in forty-seven patients. Abdominal complications. Detailed reviews of these patients' hospital charts were performed. Complications were categorized as early or late depending on if they occurred within 30 days of transplantation or later. The primary outcomes variable studied was mortality. RESULTS Fifty-three surgical consultations for abdominal symptoms were requested in these 47 patients. Twenty-two of the 47 patients (47%) with intraabdominal complications required 24 operative interventions. Overall 5-year survival was substantially worse in patients with intraabdominal complications (34%) than in those without (62%, p=0.01). There was no marked difference in the 30-day mortality for patients experiencing early (27%, 4 of 15) versus late (24%, 9 of 38) complications. Mortality in patients with intraabdominal complications was lower among those treated operatively (n=2, 9%) compared with those treated nonoperatively (n=11, 44%, p=0.02). CONCLUSIONS Mortality for patients with intraabdominal complications is high after lung transplantation. Operative intervention is well tolerated and associated with lower mortality. A high index of suspicion and timely operative intervention are necessary for the treatment of intraabdominal complications in lung transplant recipients.
Collapse
Affiliation(s)
- C Brock Miller
- Department of Surgery, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA
| | | | | | | | | | | |
Collapse
|
9
|
Odim J, Banerji A, Bahrami S, Laks H. Is Third-Time Heart Retransplantation Justifiable? Transplant Proc 2006; 38:1516-9. [PMID: 16797347 DOI: 10.1016/j.transproceed.2006.02.080] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2005] [Indexed: 11/19/2022]
Abstract
Since repeat heart transplantation traditionally carries higher risk than primary engraftment, we tested the hypothesis that third-time cardiac allograft transplantation is associated with prohibitive mortality and morbidity. The cohort of all third-time cardiac retransplants performed at our institution (n=3) and reported to UNOS from 1987 to 2002 (n=10) was reviewed. The primary endpoints were early and late mortality. Extending the study frame through 2003 captures a total of 5 and 15 third-time heart transplant recipients in UCLA and UNOS databases, respectively. Of the 15 patients undergoing third-time retransplants, preoperatively one was ventricular assist device-dependent, four were on intravenous inotropes, and two had creatinine levels greater than 2.5. Additionally, four were male recipients of female donor hearts and the mean donor ischemic time was 2.6 hours. One patient was diagnosed with acute allograft rejection, 13 with coronary artery vasculopathy/chronic rejection, and one with primary graft failure. At our institution, five patients underwent a third heart transplant. There was no early or hospital mortality. One patient died late from transplant coronary artery disease and another following a fourth allograft. The mortality rate for third-time heart allograft recipients is acceptable. These results are influenced by small sample size, younger age, case selection, and operations at select, high-volume institutions with significant experience.
Collapse
Affiliation(s)
- J Odim
- David Geffen School of Medicine at UCLA, Los Angeles, California 90095-1741, USA.
| | | | | | | |
Collapse
|
10
|
Lowes BD, Shakar SF, Metra M, Feldman AM, Eichhorn E, Freytag JW, Gerber MJ, Liard JF, Hartman C, Gorczynski R, Evans G, Linseman JV, Stewart J, Robertson AD, Roecker EB, Demets DL, Bristow MR. Rationale and design of the enoximone clinical trials program. J Card Fail 2006; 11:659-69. [PMID: 16360960 DOI: 10.1016/j.cardfail.2005.10.013] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2005] [Revised: 08/29/2005] [Accepted: 10/27/2005] [Indexed: 11/19/2022]
Abstract
BACKGROUND Chronic heart failure is a disease syndrome characterized in its advanced stages by a poor quality of life, frequent hospitalizations, and a high risk of mortality. In advanced and ultra-advanced chronic heart failure, many treatment options, such as cardiac transplantation and mechanical devices, are severely limited by availability and cost. Short-term Phase II clinical trials suggest that low-dose oral inotropic therapy with enoximone may improve hemodynamics and exercise capacity, without adversely affecting mortality, in selected subjects with advanced chronic heart failure. Based on these data, the ability of enoximone to deliver safe and efficacious palliative treatment of advanced/ultra-advanced chronic heart failure is being evaluated in Phase III clinical trials. METHODS AND RESULTS The Enoximone Clinical Trials Program is a series of 4 clinical trials designed to evaluate the safety and efficacy of oral enoximone in advanced chronic heart failure. ESSENTIAL I and II (The Studies of Oral Enoximone Therapy in Advanced Heart Failure) will investigate the effects of oral enoximone on all-cause mortality and cardiovascular hospitalization, submaximal exercise capacity, and quality of life in subjects with New York Heart Association Class III/IV chronic heart failure. EMOTE (Oral Enoximone in Intravenous Inotrope-Dependent Subjects) will evaluate the potential of oral enoximone to wean subjects with ultra-advanced chronic heart failure from chronic intravenous inotropic therapy to which they have been shown to be dependent. EMPOWER (Enoximone Plus Extended-Release Metoprolol Succinate in Subjects with Advanced Chronic Heart Failure) will explore the potential of enoximone to increase the tolerability of continuous release metoprolol in subjects shown previously to be hemodynamically intolerant to beta-blocker treatment. CONCLUSION These studies are Phase III, multicenter, randomized, double-blinded, placebo-controlled trials designed to test the general hypothesis that chronic oral administration of low doses of enoximone can produce beneficial effects in subjects with advanced or ultra-advanced chronic heart failure.
Collapse
Affiliation(s)
- Brian D Lowes
- University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Abstract
Pulmonary arterial hypertension is a disease of the small pulmonary arteries characterized by vascular narrowing and increased pulmonary vascular resistance, which eventually leads to right ventricular failure. Vasoconstriction, vascular proliferation, remodeling of the pulmonary vessels, and thrombosis are all contributing factors to the increased vascular resistance seen in this disease. Pulmonary arterial hypertension develops as a sporadic disease (idiopathic), as an inherited disorder (familial), or in association with certain conditions (collagen vascular diseases, portal hypertension, human immunodeficiency virus infection, congenital systemic-to-pulmonary shunts, ingestion of drugs or dietary products, or persistent fetal circulation). The pathogenesis of pulmonary arterial hypertension is a complicated, multifactorial process. It seems doubtful that any one factor alone is sufficient to activate the necessary pathways leading to the development of this disease. Rather, clinically apparent pulmonary arterial hypertension most likely develops after a second insult occurs in an individual who is already susceptible owing to genetic factors, environmental exposures, or acquired disorders. Currently, there is no cure for pulmonary arterial hypertension but several novel therapeutic options are now available that can improve symptoms and increase survival.
Collapse
Affiliation(s)
- Azad Raiesdana
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | | |
Collapse
|
12
|
Martínez-Dolz L, Almenar L, Martínez-Ortiz L, Arnau MA, Chamorro C, Moro J, Osa A, Rueda J, García C, Palencia M. Predictive Factors for Development of Diabetes Mellitus Post-Heart Transplant. Transplant Proc 2005; 37:4064-6. [PMID: 16386627 DOI: 10.1016/j.transproceed.2005.09.161] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
INTRODUCTION It is known that there is a high incidence of diabetes mellitus (DM) among heart transplant (HT) patients, which may be up to 30% at 5 years. The presence of DM has been associated with increased morbidity (infections, renal dysfunction, or graft vascular disease), and its development has been related primarily to immunosuppressive therapy. The objective of this study was to determine, in our experience, the presence of predictive variables for the development of DM following HT. METHODS We studied 315 consecutive non-DM patients (88.6% men, mean age 51.5 years) who underwent HT in our hospital from November 1987 to May 2003, analyzing all variables that could be related to the development of DM during follow-up. Student t-test and chi(2) test were used for univariate statistical analysis and logistic regression for multivariate analysis. RESULTS Of the 315 patients, 64 developed DM (20.3%) during a mean follow-up of 3.3 years. The univariate analysis showed that patients developing DM are older (54.9 +/- 8.7 versus 50.7 +/- 11.8 years, P = .008), have a higher body mass index (BMI) (27.3 +/- 3.8 versus 25.7 +/- 3.7, P = .003), a higher prevalence of HT (37.5% versus 23.5%, P = .023), a lower frequency of urgent HT (9.4% versus 26.2%, P = .004), are more often treated with steroids (85.9% versus 70.1%, P = .011) and tacrolimus (12.5% versus 4.4%, P = .015), and have a higher frequency of rejection episodes (71.2% versus 44.6%, P = .001). Multivariate analysis identified the following as predictive factors for the development of DM: age (OR = 1.04, P = .013), urgent HT (OR = 0.36, P = .031), treatment with tacrolimus (OR = 3.89, P = .012), and number of rejections (OR = 2.34, P = .002). CONCLUSION In our population, age, urgent HT (which had a protective effect), treatment with tacrolimus, and number of rejections were independent predictive variables for the development of DM during follow-up.
Collapse
Affiliation(s)
- L Martínez-Dolz
- Servicio de Cardiología del Hospital Universitario La Fe, Valencia, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Singhal AK, Abrams JD, Mohara J, Hasz RD, Nathan HM, Fisher CA, Furukawa S, Goldman BI. Potential Suitability for Transplantation of Hearts From Human Non–Heart-Beating Donors: Data Review From the Gift of Life Donor Program. J Heart Lung Transplant 2005; 24:1657-64. [PMID: 16210144 DOI: 10.1016/j.healun.2004.11.043] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2004] [Revised: 11/12/2004] [Accepted: 11/21/2004] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Organ availability limits use of heart transplantation for treatment for end-stage heart disease. Hearts are currently obtained from donors declared brain dead (heart-beating donors [HBDs]). Although use of hearts from non-heart-beating donors (NHBDs) could reduce the shortage, they are considered unusable because of possible peri-mortem ischemic injury. METHODS To project how use of NHBD hearts could increase heart donation, we retrospectively reviewed donor databases from the Gift of Life Donor Program (GLDP), our local organ procurement organization, from 2001 through 2003. We screened the NHBD population using conservative donor criteria, assuming an acceptable hypoxic/ischemic time (time from withdrawal of care to cross-clamp) of 30 minutes. RESULTS During the study period, there were 894 HBDs, 334 heart transplants and 119 NHBDs. NHBDs were similar to HBDs with respect to gender and ethnicity, but NHBDs were proportionately younger. Of 119 NHBDs, 55 did not meet the age criteria (< or =45 years) and 20 were eliminated because of incomplete data. Eighty-two NHBDs were cross-clamped within 30 minutes of care withdrawal. Twenty NHBDs met all cardiac donor criteria, and 14 of these 20 had hypoxic/ischemic times < or =30 minutes. Pro rata estimation for the 20 NHBDs with incomplete data suggested 7 potential additional donors. CONCLUSIONS Based on our assumptions, 12% to 18% of NHBDs in the study period (14 to 21 of 119 total) were potential heart donors, representing a 4% to 6% increase over of the number of heart transplants performed during the same time interval.
Collapse
Affiliation(s)
- Arun K Singhal
- Division of Cardiac and Thoracic Surgery, Department of Surgery, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA
| | | | | | | | | | | | | | | |
Collapse
|
14
|
McCormick J, Sims EJ, Green MW, Mehta G, Culross F, Mehta A. Comparative analysis of Cystic Fibrosis Registry data from the UK with USA, France and Australasia. J Cyst Fibros 2005; 4:115-22. [PMID: 15978536 DOI: 10.1016/j.jcf.2005.01.001] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2004] [Accepted: 01/19/2005] [Indexed: 11/29/2022]
Abstract
BACKGROUND Using the UK Cystic Fibrosis Database, we analysed the health of the UK CF paediatric population (UKPP) in terms of their biographical, clinical and infection status and compared outcomes with the US, French and Australasian CF Registries. METHODS UKPP data were collected for 2,673 patients aged less than 18 years in 2001 and used as a reference base for comparison with the most recent equivalent CF Registry reports. RESULTS Although differences exist between National CF Registries, all record similar demographic factors and key outcomes. Where plausible comparisons can be made, we report that the UKPP had the oldest median age (15.0 years), the Australasian population had the lowest median age at diagnosis (1.8 months). Approximately, double the expected number of UKPP patients (23% and 19%, respectively) fall below the 10th centile for height and weight with similar outcomes in Australasia. UKPP and French populations had similar proportions with FEV1 >80% predicted (53% and 54%, respectively). CONCLUSION Each Registry's data systems have developed independently providing a first step towards international comparisons. Standardisation of data collection criteria and definition for national CF Registries is required and we propose a standardised minimum data set, which would facilitate data integration as part of a global Registry for CF.
Collapse
Affiliation(s)
- Jonathan McCormick
- United Kingdom Cystic Fibrosis Database, Tayside Institute of Child Health, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, UK DD1 9SY.
| | | | | | | | | | | |
Collapse
|
15
|
Belvís R, Martí-Fàbregas J, Cocho D, García-Bargo MD, Franquet E, Agudo R, Brosa V, Campreciós M, Puig M, Martí-Vilalta JL. Cerebrovascular disease as a complication of cardiac transplantation. Cerebrovasc Dis 2005; 19:267-71. [PMID: 15731558 DOI: 10.1159/000084091] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2004] [Accepted: 11/24/2004] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND AND OBJECTIVES To characterize the frequency, risk factors, clinical presentation and etiological subtypes of cerebrovascular diseases (CVD) following cardiac transplantation (CTX). METHODS In a retrospective review of our CTX database (period 1984-2002), we assessed demographic data, vascular risk factors, surgery and donor details. We classified ischemic stroke (IS) using the clinical criteria of the Oxfordshire Community Stroke Project and the etiological criteria of the TOAST study. Logistic regression analysis and survival curves were carried out. RESULTS CTX was performed in a total of 314 patients (age 46 +/- 14 years, 78% male) and mean follow-up was 54 +/- 57 months. Twenty-two patients (7%) presented CVD: hemorrhagic stroke in 12%, transient ischemic attack in 28% and IS in 60%. CVD were early postoperative (less than 2 weeks) in 20% of patients and late in 80%. The clinical presentation in patients with IS was total anterior circulation (23.1%), partial anterior (38.4%), lacunar (15.4%) and posterior circulation (23.1%), and the etiological classification was large artery atherosclerosis (15.4%), cardioembolism (14.4%), small vessel disease (15.4%), unusual causes (15.4%) and undetermined cause (38.4%). The only independent predictor of CVD was a prior CVD event with an odds ratio of 8.2 (95% CI, 2.2-30.2, p < 0.02). The estimated risk of CVD at 5 years was greater (p < 0.02) in patients with prior CVD (4.1%) than in those without (1.1%). CONCLUSIONS CVD are a relatively frequent complication after CTX (7%) and usually occur in the late postoperative phase. CVD prior to transplantation increase the risk of CVD after this procedure.
Collapse
Affiliation(s)
- Robert Belvís
- Stroke Unit of the Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Affiliation(s)
- Leslie T Cooper
- Cardiovascular Division, Mayo Clinic, Rochester, Minnesota 55905, USA.
| |
Collapse
|
17
|
Abstract
The use of cyclosporine (CyA) in clinical thoracic transplantation has markedly improved the survival and quality of life of patients in the past 2 decades. In the mid-1990s a significant advance in formulation design took place with the introduction of Neoral. This new microemulsion formulation of CyA demonstrates reduced intersubject and intrasubject variability in absorption and improved oral bioavailability compared with the oil-based CyA formulation. Moreover, C2 measurements of CyA could result in an even better method to avoid overimmunosuppression. On the other hand, generic alternatives of CyA could potentially reduce costs to transplant recipients as well as to the general community. Since the initiation of tacrolimus, mycophenolate mofetil, and rapamycin, slow but expanding variations of immunosuppressive protocols have taken place. Transplantation medicine is thus becoming an increasingly exciting and innovative field, in which CyA continues to play a central role as the core immunosuppressant of choice for the majority of patients.
Collapse
Affiliation(s)
- A Zuckermann
- Department of Cardiothoracic Surgery, University of Vienna, Vienna, Austria
| | | |
Collapse
|
18
|
Abstract
Immunosuppressive therapy to prevent rejection of allografts is continually evolving in terms of development of new medications and the application of established ones. This review summarizes current knowledge regarding monitoring blood cyclosporine microemulsion (Neoral) levels 2 hours postdose (C2), as well as the relatively new immunosuppressants basiliximab and everolimus, with a particular view to lung transplantation. C2 monitoring appears to have merit over the traditional method of trough-level monitoring. Based on short-term studies in various solid organ transplant systems, C2 seems better able to predict the area under the time-concentration curve for Neoral, a benefit that extends to improved clinical outcomes. Further studies are needed to verify the robustness of clinical improvement, particularly in lung transplant recipients. Basiliximab and everolimus target stages of the immune response distinct from that targeted by Neoral. Studies conducted to date in various solid organ transplant systems suggest that use of Neoral concomitantly with one or both of these drugs provides enhanced protection from allograft rejection while improving the tolerability of immunosuppressive therapy. If these results are confirmed in lung transplant patients, improvements in lung transplantation outcomes are to be expected.
Collapse
Affiliation(s)
- C D Poirier
- Montreal Heart-Lung and Lung Transplant Program, Hôpital Notre-Dame, Montreal, Quebec, Canada
| |
Collapse
|
19
|
Murata S, Miniati DN, Kown MH, Koransky ML, Lijkwan MA, Balsam LB, Robbins RC. Superoxide Dismutase Mimetic M40401 Reduces Ischemia-Reperfusion Injury and Graft Coronary Artery Disease in Rodent Cardiac Allografts. Transplantation 2004; 78:1166-71. [PMID: 15502714 DOI: 10.1097/01.tp.0000137321.34200.fa] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND The oxidative stress associated with ischemia-reperfusion (I/R) of cardiac allografts leads to production of injurious cytokines and expression of proinflammatory adhesion molecules. This is one of the most important alloantigen-independent factors associated with graft coronary artery disease (GCAD). M40401 is a newly developed cell permeable superoxide dismutase mimetic, which has been shown to scavenge superoxide anion with highly specific and enhanced catalytic activity. We hypothesized that M40401 would exert a protective effect in I/R injury of cardiac allografts and ameliorate the progression of GCAD. METHODS Recipient ACI rats were pretreated with M40401 or vehicle control. PVG donor hearts were heterotopically transplanted into the abdomen of ACI recipients. Cardiac allografts were analyzed for adhesion molecule mRNA expression and tumor necrosis factor-alpha expression after 4 hr of reperfusion. Neutrophil infiltration was detected by myeloperoxidase activity. Intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1 mRNA were detected by reverse-transcriptase polymerase chain reaction. Immunohistochemical analysis of adhesion molecule expression was also performed. Additional grafts were procured 90 days after transplantation and assessed for the development of GCAD by computer-assisted image analysis. RESULTS In the M40401-treated group, adhesion molecule expression was significantly less than in the vehicle control group. Treated grafts also had lower myeloperoxidase activity and tumor necrosis factor-alpha concentration compared with controls. Neointimal proliferation and intima to media ratios in M40401-treated allografts were significantly decreased compared with controls. CONCLUSIONS Selective removal of superoxide anion by M40401 results in inhibition of I/R injury. Furthermore, M40401 treatment decreases the development of oxidative stress-associated GCAD. This treatment strategy may have broad cardioprotective applications for all cardiac operations in addition to cardiac transplantation.
Collapse
Affiliation(s)
- Seiichiro Murata
- Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA 94305, USA
| | | | | | | | | | | | | |
Collapse
|
20
|
Colson YL, Xu H, Huang Y, Ildstad ST. Mixed Xenogeneic Chimerism Induces Donor-Specific Humoral and Cellular Immune Tolerance for Cardiac Xenografts. THE JOURNAL OF IMMUNOLOGY 2004; 173:5827-34. [PMID: 15494536 DOI: 10.4049/jimmunol.173.9.5827] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Xenotransplantation has been suggested as a potential solution to the critical shortage of donor organs. However, success has been limited by the vigorous rejection response elicited against solid organs transplanted across species barriers. Mixed xenogeneic bone marrow chimeras resulting from the transplantation of a mixture of host and donor marrow (B10 mouse + F344 rat --> B10 mouse) results in donor-specific cross-species transplantation tolerance for subsequent nonvascularized skin and islet grafts. Furthermore, compared with fully xenogeneic chimeras (rat --> mouse), mixed xenogeneic chimeras exhibit superior immunocompetence for infectious agents in vivo and in vitro, suggesting that the immune system is intact. The ability to establish long-term humoral and cellular tolerance for primarily vascularized xenografts in vivo, in the setting of both recipient and donor Ig and effector cell production, has not previously been characterized. Mixed xenogeneic chimeras exhibit donor-specific humoral tolerance as evident by the absence of anti-donor Ab and Ab-dependent donor-specific cytotoxicity in vitro and intravascular IgM deposition within donor-strain (F344) cardiac xenografts in vivo. F344 cardiac xenografts are accepted (median > or =180 days) without clinical or histologic evidence of rejection, suggesting cellular tolerance. In contrast, MHC-disparate third-party mouse (B10.BR) and rat (ACI or WF) grafts are rejected (median of 23 and 41 days, respectively) in association with extensive mononuclear cell infiltration and vascular deposits of mouse IgM. These results demonstrate that mixed xenogeneic chimerism establishes donor-specific humoral and cellular tolerance and permits the successful transplantation of even primarily vascularized xenografts in the setting of intact Ab production.
Collapse
Affiliation(s)
- Yolonda L Colson
- Department of Surgery, Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA.
| | | | | | | |
Collapse
|
21
|
Lungentransplantation im fortgeschrittenen Lebensalter. ZEITSCHRIFT FUR HERZ THORAX UND GEFASSCHIRURGIE 2004. [DOI: 10.1007/s00398-004-1101-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
22
|
Doyle RL, McCrory D, Channick RN, Simonneau G, Conte J. Surgical Treatments/Interventions for Pulmonary Arterial Hypertension. Chest 2004; 126:63S-71S. [PMID: 15249495 DOI: 10.1378/chest.126.1_suppl.63s] [Citation(s) in RCA: 115] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
While considerable advances have been achieved in the medical treatment of pulmonary arterial hypertension (PAH) over the past decade, surgical and interventional approaches continue to have important roles in those patients for whom medical therapy is unavailable or has been unsuccessful. These techniques include pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension, thoracic transplantation, and atrial septostomy. This chapter will provide evidence-based recommendations for the selection and timing of surgical and interventional treatments of PAH for physicians involved in the care of these complex patients.
Collapse
Affiliation(s)
- Ramona L Doyle
- Pulmonary and Critical Care Medicine, H3147 Stanford University School of Medicine, Palo Alto, CA 94305, USA.
| | | | | | | | | |
Collapse
|
23
|
Abstract
Much progress has been made in heart and lung transplantation over recent decades. The immune mechanisms that result in allograft rejection are now better understood, and the development of immunosuppressant therapies has decreased recipient mortality among transplant recipients. During the 1980s, immunosuppressant therapy primarily involved the use of corticosteroids and cyclosporine. However, while survival rates increased among transplant recipients, many patients experienced primary graft failures, acute and chronic rejection, as well as death. Until the introduction of tacrolimus in the early 1990s, all patients received the same immunosuppressant regimen, regardless of its effectiveness. Tacrolimus therapy has contributed much to the success rates of both heart and lung transplantation, and by 2001, it had become the preeminent immunosuppressant agent used in lung transplantation.
Collapse
Affiliation(s)
- Edward R Garrity
- Lung Transplantation Program, Loyola University Hospital, Maywood, IL, USA
| | | |
Collapse
|
24
|
Garcia-Pachon E, Padilla-Nava I. Predicting outcomes in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:2308-10; author reply 2308-10. [PMID: 15163786 DOI: 10.1056/nejmc040790] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
25
|
Abstract
The use of calcineurin inhibitors (CNIs; cyclosporine and tacrolimus) has dramatically increased medium-term life expectancy after heart transplantation but has had only limited impact on long-term outcomes for heart transplant recipients. The original oil-based formulation of cyclosporine has been superceded by a microemulsion formulation (Neoral), which has more predictable pharmacokinetics and allows more precise dose-tailoring. Cyclosporine microemulsion and tacrolimus (Prograf) have a similar efficacy in the prevention of acute rejection of heart transplants, but their use is accompanied by nephrotoxicity and by cardiovascular side effects. The efficacy of immunosuppression can be improved by adjunctive therapy, such as azathioprine, mycophenolate mofetil (MMF; Cellcept), corticosteroids, and induction therapy. One of the most important predictors of patient mortality at >5 years after heart transplantation is cardiac allograft vasculopathy (CAV)/late graft failure, which accounts for 31% of deaths. Neither cyclosporine nor tacrolimus have been shown to prevent the development of CAV. In terms of efficacy, MMF provides a modest advantage over azathioprine in preventing CAV, and the combination of cyclosporine plus MMF results in significantly lower mortality than cyclosporine plus azathioprine. Overall, CNIs have multiple cardiovascular side effects, such as hypertension, hyperlipidemia and new-onset diabetes after transplantation, although cyclosporine and tacrolimus have somewhat different cardiovascular side-effect profiles. The challenge in choosing the best immunosuppressive regimen is to balance efficacy and safety to optimize graft and patient survival over the course of many decades. Because cyclosporine and tacrolimus have similar efficacy against acute rejection the choice of CNI for heart transplant recipients should be based on the relative risk of cardiovascular and renal side effects.
Collapse
Affiliation(s)
- Anne Keogh
- Victor Chang Cardiac Research Institute and Heart Lung Transplant Unit, St. Vincent's Hospital, Darlinghurst, New South Wales, Australia.
| |
Collapse
|
26
|
Cantu E, Davis RD. Lung Transplantation: Timing, Perioperative Considerations and Postoperative Outcome. ACTA ACUST UNITED AC 2004. [DOI: 10.21693/1933-088x-3.1.9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- Edward Cantu
- Department of Surgery, Duke University Medical Center, Durham, North Carolina
- Dr. Cantu was supported by a grant from the National Institutes of Health (1F32 HL 71457-01)
| | - R. Duane Davis
- Department of Surgery, Duke University Medical Center, Durham, North Carolina
| |
Collapse
|
27
|
|